about
Nerolidol: A Sesquiterpene Alcohol with Multi-Faceted Pharmacological and Biological ActivitiesCandida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agentsAntifungal Susceptibility in Serum and Virulence Determinants of Candida Bloodstream Isolates from Hong KongAntifungal prophylaxis in pediatric hematology/oncology: new choices & new data.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Targeted versus universal antifungal prophylaxis among liver transplant recipientsInvasive fungal infections in acute leukemia.Invasive fungal infections and antifungal therapies in solid organ transplant recipients.Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Complexity of interactions between voriconazole and antiretroviral agents.Current options in antifungal pharmacotherapy.Induction effects of ritonavir: implications for drug interactions.Colchicine-Induced Acute Neuromyopathy in a Patient Using Concomitant Fluconazole: Case Report and Literature Review.Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.Invasive mold infections: recent advances in management approaches.Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.Management of drug and food interactions with azole antifungal agents in transplant recipients.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Management of fungal lung disease in the immunocompromised.Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.Antifungal susceptibility testing: a primer for clinicians.Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review.Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B.Immunodetection of fungal and oomycete pathogens: established and emerging threats to human health, animal welfare and global food security.Future directions for anti-biofilm therapeutics targeting Candida.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia.Medically important fungi respond to azole drugs: an update.Systemic Antifungal Agents: Current Status and Projected Future Developments.Antifungal agents and liver toxicity: a complex interaction.Potential of novel drug delivery systems in the management of topical candidiasis.Hepatotoxicity of Antimycotics Used for Invasive Fungal Infections: In Vitro Results.Treatment of Disseminated Aspergillosis with Posaconazole in 10 Dogs.In vitro susceptibility of dermatophytes isolated from patients with end-stage renal disease: a case-control study.CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration.[Reevaluation of Candida susceptibility to amphotericin B: comparative study using isolates from three hospitals in the state of Rio Grande do Sul].Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.Diversity of Cell Wall Related Proteins in Human Pathogenic Fungi.Filter Adsorption of Anidulafungin to a Polysulfone-Based Hemofilter During CVVHD In Vitro.
P2860
Q26748306-0D48D12C-B869-4CEA-A3A5-A50EEE4C70A7Q26863344-FCE674E1-2C73-4651-8ABB-370E591AED7CQ28388030-79A0DF22-E389-4A44-B77C-F18998D50E72Q33559503-54A6A259-596A-4F38-B045-907F1DA5D977Q34505582-D3654D22-3BAA-4F2B-95C6-1228ED7DF922Q35194743-288000AF-8EEC-419C-9B19-3EC52C44D31AQ36612597-F1E5B4CA-2BFE-4CC6-AFCB-C89ADB11B955Q36872848-C74817E9-7FDA-4416-8FA2-FAE07751D808Q37096795-C93C049B-E0D9-4B40-9C95-45AB52A1B74FQ37138857-CCDDE770-6932-4594-8423-5E570DC5F17DQ37151326-C0D142D6-2C02-406B-8B47-6318D1C8AB1CQ37199533-D3F19809-7607-42E6-9133-25CED08BBDC1Q37218927-49191869-3BE3-4020-93CD-4F6E235786EEQ37404840-6BB1876E-31EE-48F9-B8B1-4C3C3294618AQ37428946-53092076-5390-4DEA-9A6F-308B41334799Q37621550-A2A18555-9B78-43A4-AC1C-61400874BD59Q37775009-17293175-91CB-44A0-8074-A0F1B947FF22Q37904672-E1464FBF-4C82-40B0-B53A-DAAF5737EEFBQ37909774-158152E0-F4FB-490F-B384-612585F3FC1FQ37918556-25823AB5-9D2A-4A96-A8F7-9E71054463CCQ38061087-D871C2B6-0F07-41C1-953A-71EBC8722A8BQ38073201-2948E220-E732-4366-BC4E-1390FE5255D9Q38079194-0B507A64-0BBA-4124-8975-D80B2A867A0DQ38111802-3733E4E0-C6BD-4E00-B43B-A319D252B674Q38186068-7398593B-8CFA-4594-AE0D-7D1D4ADE9393Q38193337-D6B02C70-D624-449F-BA7C-42DC7CF7CDB1Q38535647-51251D9E-EAA3-4B1F-8B8F-8BCFB13077EFQ38559208-9F405899-05BB-48B4-B921-59F68D842A4DQ38796140-AADE7ADC-27D6-46DD-B909-7BF5C19DB65EQ38858839-E6FEA150-90FC-4DAA-8CEC-9AC3794A08E3Q39315981-7D03F011-EBF1-497C-B87D-CCCDA6F82ADEQ40225550-89DCA54D-8951-49F8-A731-EBF3BECD4CEEQ40323166-A2C6CEC7-3720-41E0-92CF-5D7C9FB7AA45Q43753731-FC23FC92-E310-4A55-9064-E081A58FDA16Q44273424-D2CBAA60-B781-42C2-A3C6-4CC05A5CBE24Q44311698-EB70166B-0119-4030-B703-BDCBAE426739Q46681089-E256A264-6335-4ABC-A64C-727164B3E9D1Q46826187-A0E9782C-0ABA-4507-83DD-1C1598D61771Q48163355-7C83C93E-D4E4-47B8-8CD0-466FB4B54DC3Q48192025-238392A8-DF8A-4C99-96A5-878D96DC4F75
P2860
description
im August 2006 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2006
@uk
name
Pharmacology of Systemic Antifungal Agents
@en
Pharmacology of Systemic Antifungal Agents
@nl
type
label
Pharmacology of Systemic Antifungal Agents
@en
Pharmacology of Systemic Antifungal Agents
@nl
prefLabel
Pharmacology of Systemic Antifungal Agents
@en
Pharmacology of Systemic Antifungal Agents
@nl
P2093
P2860
P356
P1476
Pharmacology of Systemic Antifungal Agents
@en
P2093
Craig Martin
David Andes
Elizabeth S. Dodds Ashley
James S. Lewis
P2860
P304
P356
10.1086/504492
P407
P433
Supplement_1
P577
2006-08-01T00:00:00Z